在非心脏手术患者中,STOP或NOT试验没有发现继续或停止RAS抑制剂对术后结果有显著影响. STOP-or-NOT trial finds no significant impact on postoperative outcomes for continuing or discontinuing RAS inhibitors in non-cardiac surgery patients.

在需要进行重大非心脏手术的患者中进行的STOP或NOT试验发现,无论是继续还是停止服用氨酸-血管新生系统 (RAS) 抑制剂,都没有显著影响术后结果. The STOP-or-NOT trial, conducted among patients requiring major non-cardiac surgery, found that neither continuing nor discontinuing renin-angiotensin system (RAS) inhibitors significantly impacted postoperative outcomes. 鉴于这两个群体都面临类似的全因死亡率和主要手术后并发症,建议采取量身定做的办法,继续使用RASi,同时考虑到个别病人因素、外科和病人的偏好。 With both groups experiencing similar rates of all-cause mortality and major postoperative complications, a tailored approach to RASi continuation is recommended, considering individual patient factors, surgery specifics, and patient preferences.